Abstract
Abstract: :
Purpose: To evaluate the efficacy of Timolol Maleate, Acetyl Choline and Latanoprost in preventing ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation among glaucoma and non–glaucoma patients. Methods: This prospective randomized double–masked clinical trial comprised glaucoma (n=22) and non–glaucoma (n=95) patients with uncomplicated cataract having phacoemulsification with PCIOL implantation by two experienced surgeons. They were randomly assigned to1of 4 groups in which postoperative treatment of either Timolol Maleate 0.5%, Acetyl Choline, Latanoprost 0.005% or no treatment was applied once. Intraocular pressure (IOP) was measured 4, 8, 24 hours and 1 week postoperatively by Goldmann applanation tonometry. Results: Intraocular pressure was higher among the untreated glaucoma group 4, 8 and 24 hours postoperatively (mean IOP: 19.2 ±5.7, 19.2± 3.4 and 18.2±6.4 mmHg, respectively) compared to the untreated non–glaucoma group (mean IOP: 16±3.6, 16±3.6, 14.3±3.8 mmHg, respectively). Intraocular pressure was higher 4, 8, 24 hours and 1 week postoperatively among the Timolol Maleate glaucoma group compared to the Timolol Maleate non–glaucoma group, and was significantly higher 24 hours postoperatively. Intraocular pressure was higher 4, 8 hours and 1 week postoperatively among the Acetyl Choline glaucoma group compared to the Acetyl Choline non–glaucoma group, and was significantly higher 4 hours postoperatively. In addition, intraocular pressure was higher 4, 24 hours and 1 week postoperatively among the Latanoprost glaucoma group compared o the Latanoprost non–glaucoma group, and significantly higher 1 week postoperatively. Among the non–glaucoma group those who were treated with Timolol maleate had a significant intraocular pressure reduction 24 hours postoperatively (mean IOP: 12.1±3.8 mmHg) compared to those treated with Latanoprost ( mean IOP:15.9±4.3 mmHg). Conclusions: IOP measurement postoperatively seemed to be higher among glaucoma patients compared to non–glaucoma patients. Prophylactic use of topical Timolol Maleate 0.5% after phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation among non–glaucoma patients appears to offer better IOP control 24 hours postoperatively than other medications.
Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • cataract